Global Whole Exome Sequencing Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-31
- Report ID: 144141
- Pages: 225
-
Format:
Short Description
Global Whole Exome Sequencing Market, Component (Whole Exome Sequencing, Second-Generation Sequencing, Third-Generation Sequencing), Product And Services (Systems, Kits, Services), Application (Diagnostics, Drug Discovery And Development, Personalized Medicine, Agriculture & Animal Research, Others), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Clinical Laboratories, Others), Distribution Channel (Direct Trade, Retail Sales, Others). Industry Trends and Forecast to 2029.
Market Definition:
Whole exome sequencing is a genomic technique indicated for sequencing of all the protein-coding region of genes in a genome. Whole exome sequencing (WES) is available to physicians and patients who are looking for a unifying diagnosis of multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exon (or protein-coding) regions of an individuals genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES (Whole-exome sequencing). The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants making this method a cost-effective alternative to whole-genome sequencing.
Exome sequencing is used across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.
Market Segmentation:
Global whole exome sequencing market is categorized into five notable segments which are based on component, product and service, application, end user and distribution channel. In 2022, second generation sequencing segment is expected to dominate the market due to technological advancement in the whole exome sequencing.
On the basis of component, the global whole exome sequencing market is segmented into second generation sequencing and third-generation sequencing.
On the basis of product and service, the global whole exome sequencing market is segmented into systems, kits and services.
On the basis of application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
On the basis of end user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
On the basis of distribution channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.
Market Players
The key market players for the global whole exome sequencing market are listed below:
Beckman Coulter, Inc.
BIONEER CORPORATION
Eurofins Scientific
ExoDx (a part of Bio-Techne)
FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd)
QIAGEN
GeneFirst Limited
CeGaT GmbH
Illumina, Inc.
Meridian
Merck KGaA
SOPHiA GENETICS
Azenta Life Sciences
CD Genomics
Twist Bioscience
Thermo Fisher Scientific Inc.
PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.)
GeneDx, LLC
Psomagen
Integrated DNA Technologies, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF GLOBAL WHOLE EXOME SEQUENCING (WES) MARKET 34
1.4 CURRENCY AND PRICING 36
1.5 LIMITATIONS 36
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 DBMR TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 MARKET APPLICATION COVERAGE GRID 48
2.8 PRODUCT TYPE LIFELINE CURVE 49
2.9 DBMR MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHT 58
4.1 PORTERS FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
4.3 INDUSTRIAL INSIGHTS: 61
4.4 CONCLUSION 62
5 GLOBAL WHOLE EXOME SEQUENCING MARKET: REGULATIONS 63
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 67
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 67
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 67
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 68
6.2 RESTRAINTS 69
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 69
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 69
6.3 OPPORTUNITIES 70
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 70
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 70
6.4 CHALLENGES 71
6.4.1 LACK OF SKILLED PROFESSIONALS 71
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 71
7 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 72
7.1 OVERVIEW 73
7.2 SECOND-GENERATION SEQUENCING 76
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 77
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 77
7.3 THIRD-GENERATION SEQUENCING 78
8 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 79
8.1 OVERVIEW 80
8.2 SYSTEMS 83
8.2.1 HISEQ SERIES 84
8.2.1.1 HISEQ 2500 84
8.2.1.2 HISEQ 1500 84
8.2.2 MISEQ SERIES 84
8.2.3 ION TORRENT PLATFORMS 85
8.2.3.1 ION PROTON 85
8.2.3.2 ION PGM 85
8.2.4 OTHERS 85
8.3 KITS 85
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 86
8.3.2 LIBRARY PREPARATION KITS 86
8.3.3 TARGET ENRICHMENT KITS 87
8.3.4 OTHERS 87
8.4 SERVICES 87
8.4.1 SEQUENCING SERVICES 88
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 88
8.4.3 OTHERS 88
9 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 89
9.1 OVERVIEW 90
9.2 DRUG DISCOVERY AND DEVELOPMENT 93
9.3 AGRICULTURE & ANIMAL RESEARCH 94
9.4 DIAGNOSTICS 94
9.5 PERSONALIZED MEDICINE 95
9.6 OTHERS 96
10 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY END USER 97
10.1 OVERVIEW 98
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 101
10.3 ACADEMIC & RESEARCH INSTITUTES 102
10.4 HOSPITALS AND CLINICS 102
10.5 CLINICAL LABORATORIES 103
10.6 OTHERS 104
11 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 105
11.1 OVERVIEW 106
11.2 DIRECT TRADE 109
11.3 RETAIL SALES 109
11.4 OTHERS 111
12 GLOBAL WHOLE EXOME SEQUENCING MARKET, BY REGION 112
12.1 OVERVIEW 113
12.2 NORTH AMERICA 118
12.2.1 U.S. 126
12.2.2 CANADA 129
12.2.3 MEXICO 132
12.3 EUROPE 135
12.3.1 GERMANY 143
12.3.2 FRANCE 147
12.3.3 U.K. 150
12.3.4 RUSSIA 154
12.3.5 ITALY 157
12.3.6 SPAIN 160
12.3.7 TURKEY 163
12.3.8 NETHERLANDS 166
12.3.9 SWITZERLAND 170
12.3.10 BELGIUM 174
12.3.11 REST OF EUROPE 178
12.4 ASIA-PACIFIC 179
12.4.1 CHINA 187
12.4.2 JAPAN 190
12.4.3 INDIA 193
12.4.4 SOUTH KOREA 196
12.4.5 AUSTRALIA 200
12.4.6 SINGAPORE 204
12.4.7 THAILAND 208
12.4.8 INDONESIA 212
12.4.9 PHILIPPINES 216
12.4.10 MALAYSIA 220
12.4.11 VIETNAM 224
12.4.12 REST OF ASIA-PACIFIC 228
12.5 SOUTH AMERICA 229
12.5.1 BRAZIL 237
12.5.2 ARGENTINA 240
12.5.3 REST OF SOUTH AMERICA 244
12.6 MIDDLE EAST AND AFRICA 245
12.6.1 SOUTH AFRICA 253
12.6.2 SAUDI ARABIA 257
12.6.3 U.A.E 261
12.6.4 ISRAEL 264
12.6.5 EGYPT 267
12.6.6 REST OF MIDDLE EAST AND AFRICA 270
13 GLOBAL WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 271
13.1 COMPANY SHARE ANALYSIS: GLOBAL 271
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 272
13.3 COMPANY SHARE ANALYSIS: EUROPE 273
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 274
14 COMPANY PROFILE 275
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 275
14.1.1 COMPANY SNAPSHOT 275
14.1.2 REVENUE ANALYSIS 275
14.1.3 COM PANY SHARE ANALYSIS 276
14.1.4 PRODUCT PORTFOLIO 276
14.1.5 RECENT DEVELOPMENTS 276
14.2 MERCK KGAA 278
14.2.1 COMPANY SNAPSHOT 278
14.2.2 REVENUE ANALYSIS 278
14.2.3 COM PANY SHARE ANALYSIS 279
14.2.4 PRODUCT PORTFOLIO 279
14.2.5 RECENT DEVELOPMENTS 279
14.3 EXODX (A PART OF BIO-TECHNE) 280
14.3.1 COMPANY SNAPSHOT 280
14.3.2 REVENUE ANALYSIS 280
14.3.3 COM PANY SHARE ANALYSIS 281
14.3.4 PRODUCT PORTFOLIO 281
14.3.5 RECENT DEVELOPMENTS 281
14.4 THERMO FISHER SCIENTIFIC INC. 282
14.4.1 COMPANY SNAPSHOT 282
14.4.2 REVENUE ANALYSIS 282
14.4.3 COM PANY SHARE ANALYSIS 283
14.4.4 PRODUCT PORTFOLIO 283
14.4.5 RECENT DEVELOPMENTS 283
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 284
14.5.1 COMPANY SNAPSHOT 284
14.5.2 REVENUE ANALYSIS 284
14.5.3 COM PANY SHARE ANALYSIS 285
14.5.4 PRODUCT PORTFOLIO 285
14.5.5 RECENT DEVELOPMENTS 285
14.6 AZENTA US, INC. 287
14.6.1 COMPANY SNAPSHOT 287
14.6.2 PRODUCT PORTFOLIO 287
14.6.3 RECENT DEVELOPMENTS 287
14.7 BECKMAN COULTER, INC 289
14.7.1 COMPANY SNAPSHOT 289
14.7.2 REVENUE ANALYSIS 289
14.7.3 PRODUCT PORTFOLIO 290
14.7.4 RECENT DEVELOPMENTS 290
14.8 BIONEER CORPORATION 291
14.8.1 COMPANY SNAPSHOT 291
14.8.2 REVENUE ANALYSIS 291
14.8.3 PRODUCT PORTFOLIO 292
14.8.4 RECENT DEVELOPMENTS 292
14.9 CD GENOMICS 293
14.9.1 COMPANY SNAPSHOT 293
14.9.2 PRODUCT PORTFOLIO 293
14.9.3 RECENT DEVELOPMENTS 293
14.10 CEGAT GMBH 294
14.10.1 COMPANY SNAPSHOT 294
14.10.2 PRODUCT PORTFOLIO 294
14.10.3 RECENT DEVELOPMENTS 294
14.11 EUROFINS SCIENTIFIC 295
14.11.1 COMPANY SNAPSHOT 295
14.11.2 REVENUE ANALYSIS 295
14.11.3 PRODUCT PORTFOLIO 296
14.11.4 RECENT DEVELOPMENTS 296
14.12 GENEDX, LLC 297
14.12.1 COMPANY SNAPSHOT 297
14.12.2 PRODUCT PORTFOLIO 297
14.12.3 RECENT DEVELOPMENTS 297
14.13 GENEFIRST LIMITED. 299
14.13.1 COMPANY SNAPSHOT 299
14.13.2 PRODUCT PORTFOLIO 299
14.13.3 RECENT DEVELOPMENTS 299
14.14 ILLUMINA, INC 301
14.14.1 COMPANY SNAPSHOT 301
14.14.2 REVENUE ANALYSIS 301
14.14.3 PRODUCT PORTFOLIO 302
14.14.4 RECENT DEVELOPMENTS 302
14.15 INTEGRATED DNA TECHNOLOGIES, INC. 304
14.15.1 COMPANY SNAPSHOT 304
14.15.2 PRODUCT PORTFOLIO 304
14.15.3 RECENT DEVELOPMENTS 304
14.16 MERIDIAN BIOSCIENCE, INC. 306
14.16.1 COMPANY SNAPSHOT 306
14.16.2 REVENUE ANALYSIS 306
14.16.3 PRODUCT PORTFOLIO 307
14.16.4 RECENT DEVELOPMENTS 307
14.17 PSOMAGEN 308
14.17.1 COMPANY SNAPSHOT 308
14.17.2 REVENUE ANALYSIS 308
14.17.3 PRODUCT PORTFOLIO 308
14.17.4 RECENT DEVELOPMENTS 309
14.18 QIAGEN 310
14.18.1 COMPANY SNAPSHOT 310
14.18.2 REVENUE ANALYSIS 310
14.18.3 PRODUCT PORTFOLIO 311
14.18.4 RECENT DEVELOPMENTS 311
14.19 SOPHIA GENETICS 312
14.19.1 COMPANY SNAPSHOT 312
14.19.2 REVENUE ANALYSIS 312
14.19.3 PRODUCT PORTFOLIO 313
14.19.4 RECENT DEVELOPMENTS 313
14.20 TWIST BIOSCIENCE 314
14.20.1 COMPANY SNAPSHOT 314
14.20.2 REVENUE ANALYSIS 314
14.20.3 PRODUCT PORTFOLIO 315
14.20.4 RECENT DEVELOPMENTS 315
15 QUESTIONNAIRE 317
16 RELATED REPORTS 320
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
